Allogene Historical Financial Ratios

ALLO Stock  USD 1.87  0.03  1.63%   
Allogene Therapeutics is presently reporting on over 93 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Dividend Yield of 0.0, PTB Ratio of 1.03 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Allogene Therapeutics financial condition quickly.
Quick RatioCurrent Ratio100%
  
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.

About Allogene Financial Ratios Analysis

Allogene TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Allogene Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Allogene financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Allogene Therapeutics history.

Allogene Therapeutics Financial Ratios Chart

At this time, Allogene Therapeutics' Price Earnings To Growth Ratio is very stable compared to the past year. As of the 22nd of December 2024, Ebt Per Ebit is likely to grow to 1.10, while Book Value Per Share is likely to drop 3.10.
Add Fundamental
Price To Sales RatioDividend Yield
Ptb RatioDays Sales Outstanding
Book Value Per ShareFree Cash Flow Yield
Invested CapitalOperating Cash Flow Per Share
Average PayablesStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Ev To SalesFree Cash Flow Per Share
RoicInventory Turnover
Net Income Per ShareDays Of Inventory On Hand
Payables TurnoverSales General And Administrative To Revenue
Average InventoryResearch And Ddevelopement To Revenue
Capex To RevenueCash Per Share
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioDays Payables Outstanding
Net Current Asset ValueIncome Quality
RoeTangible Asset Value
Ev To Operating Cash FlowPe Ratio
Return On Tangible AssetsEv To Free Cash Flow
Earnings YieldIntangibles To Total Assets
Net Debt To E B I T D ACurrent Ratio
Tangible Book Value Per ShareReceivables Turnover
Graham NumberShareholders Equity Per Share
Debt To EquityCapex Per Share
Graham Net NetAverage Receivables
Revenue Per ShareInterest Debt Per Share
Debt To AssetsEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Operating CyclePrice Book Value Ratio
Price Earnings To Growth RatioDays Of Payables Outstanding
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioCash Conversion Cycle
Operating Cash Flow Sales RatioDays Of Inventory Outstanding
Days Of Sales OutstandingFree Cash Flow Operating Cash Flow Ratio
Cash Flow Coverage RatiosPrice To Book Ratio
Fixed Asset TurnoverCapital Expenditure Coverage Ratio
Price Cash Flow RatioEnterprise Value Multiple
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On Equity
JavaScript chart by amCharts 3.21.15201520205001K1.5K2K2.5K3K3.5K4K4.5K5K5.5K 024681012141618202224 -0.45-0.40-0.35-0.30-0.25-0.20-0.15-0.10-0.05 5001K1.5K2K2.5K3K3.5K4K4.5K5K5.5K 510152025303540 246810121416182022
JavaScript chart by amCharts 3.21.15Price To Sales Ratiototal: 15KBook Value Per Sharetotal: 57.24638946074136Free Cash Flow Yieldtotal: -1.7772069917444695Ev To Salestotal: 13.2KPayables Turnovertotal: 89.30483500994997Capex To Revenuetotal: 52.43481809915812

Price To Sales Ratio

Price to Sales Ratio is figured by comparing Allogene Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Allogene Therapeutics sales, a figure that is much harder to manipulate than other Allogene Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.

Book Value Per Share

The ratio of equity available to common shareholders divided by the number of outstanding shares. This measure represents the value per share of a company according to its financial statements.

Free Cash Flow Yield

A financial solvency ratio that compares the free cash flow per share a company is expected to earn against its market value per share, calculated as free cash flow per share divided by market price per share.

Ev To Sales

The Enterprise Value to Sales ratio, a valuation metric used to compare the value of a company, including debt and excluding cash, to its sales revenue.

Payables Turnover

A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.

Capex To Revenue

The ratio of a company's capital expenditures to its total revenue, indicating how much of the revenue is used for acquiring or maintaining physical assets.
Most ratios from Allogene Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Allogene Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.At this time, Allogene Therapeutics' Price Earnings To Growth Ratio is very stable compared to the past year. As of the 22nd of December 2024, Ebt Per Ebit is likely to grow to 1.10, while Book Value Per Share is likely to drop 3.10.
 2010 2023 2024 (projected)
Interest Debt Per Share0.120.10.096
Revenue Per Share0.286.05E-45.75E-4

Allogene Therapeutics fundamentals Correlations

0.52-0.02-0.99-0.22-0.460.520.970.39-0.99-0.5-0.230.620.890.88-0.710.90.840.350.94-0.670.52-0.980.220.52-0.97
0.520.66-0.540.430.221.00.480.29-0.51-0.64-0.740.870.440.51-0.860.430.4-0.320.64-0.870.82-0.42-0.491.0-0.37
-0.020.660.020.280.210.66-0.030.080.04-0.13-0.960.21-0.030.0-0.18-0.06-0.04-0.250.03-0.210.190.07-0.270.660.09
-0.99-0.540.020.20.44-0.54-0.99-0.40.980.550.23-0.63-0.94-0.810.72-0.89-0.91-0.34-0.940.68-0.550.98-0.19-0.540.96
-0.220.430.280.20.760.43-0.210.290.29-0.12-0.130.46-0.17-0.19-0.36-0.46-0.15-0.93-0.16-0.450.360.37-0.910.430.44
-0.460.220.210.440.760.22-0.43-0.410.440.24-0.040.21-0.37-0.43-0.12-0.66-0.36-0.93-0.42-0.170.220.53-0.920.220.57
0.521.00.66-0.540.430.220.480.29-0.51-0.64-0.740.870.440.51-0.860.430.4-0.320.64-0.870.82-0.42-0.491.0-0.37
0.970.48-0.03-0.99-0.21-0.430.480.36-0.97-0.47-0.210.570.980.73-0.660.840.920.330.89-0.620.46-0.970.20.48-0.96
0.390.290.08-0.40.29-0.410.290.36-0.27-0.52-0.120.350.340.39-0.340.340.360.060.41-0.40.2-0.280.070.29-0.25
-0.99-0.510.040.980.290.44-0.51-0.97-0.270.480.22-0.6-0.91-0.840.69-0.9-0.85-0.38-0.940.64-0.530.99-0.23-0.510.98
-0.5-0.64-0.130.55-0.120.24-0.64-0.47-0.520.480.23-0.76-0.45-0.460.77-0.67-0.4-0.12-0.730.76-0.770.440.09-0.640.4
-0.23-0.74-0.960.23-0.13-0.04-0.74-0.21-0.120.220.23-0.32-0.18-0.230.32-0.19-0.160.08-0.260.32-0.290.190.14-0.740.18
0.620.870.21-0.630.460.210.870.570.35-0.6-0.76-0.320.520.6-0.990.520.47-0.330.76-1.00.94-0.51-0.520.87-0.45
0.890.44-0.03-0.94-0.17-0.370.440.980.34-0.91-0.45-0.180.520.58-0.610.750.950.280.8-0.580.41-0.910.150.44-0.9
0.880.510.0-0.81-0.19-0.430.510.730.39-0.84-0.46-0.230.60.58-0.650.840.60.330.88-0.620.57-0.820.220.51-0.81
-0.71-0.86-0.180.72-0.36-0.12-0.86-0.66-0.340.690.770.32-0.99-0.61-0.65-0.61-0.570.23-0.830.99-0.940.610.43-0.860.55
0.90.43-0.06-0.89-0.46-0.660.430.840.34-0.9-0.67-0.190.520.750.84-0.610.710.620.94-0.550.52-0.910.440.43-0.91
0.840.4-0.04-0.91-0.15-0.360.40.920.36-0.85-0.4-0.160.470.950.6-0.570.710.280.75-0.530.44-0.850.160.4-0.84
0.35-0.32-0.25-0.34-0.93-0.93-0.320.330.06-0.38-0.120.08-0.330.280.330.230.620.280.330.3-0.25-0.470.96-0.32-0.53
0.940.640.03-0.94-0.16-0.420.640.890.41-0.94-0.73-0.260.760.80.88-0.830.940.750.33-0.790.72-0.910.130.64-0.89
-0.67-0.87-0.210.68-0.45-0.17-0.87-0.62-0.40.640.760.32-1.0-0.58-0.620.99-0.55-0.530.3-0.79-0.920.550.49-0.870.49
0.520.820.19-0.550.360.220.820.460.2-0.53-0.77-0.290.940.410.57-0.940.520.44-0.250.72-0.92-0.43-0.470.82-0.38
-0.98-0.420.070.980.370.53-0.42-0.97-0.280.990.440.19-0.51-0.91-0.820.61-0.91-0.85-0.47-0.910.55-0.43-0.34-0.421.0
0.22-0.49-0.27-0.19-0.91-0.92-0.490.20.07-0.230.090.14-0.520.150.220.430.440.160.960.130.49-0.47-0.34-0.49-0.4
0.521.00.66-0.540.430.221.00.480.29-0.51-0.64-0.740.870.440.51-0.860.430.4-0.320.64-0.870.82-0.42-0.49-0.37
-0.97-0.370.090.960.440.57-0.37-0.96-0.250.980.40.18-0.45-0.9-0.810.55-0.91-0.84-0.53-0.890.49-0.381.0-0.4-0.37
Click cells to compare fundamentals

Allogene Therapeutics Account Relationship Matchups

Allogene Therapeutics fundamentals Accounts

201920202021202220232024 (projected)
Ptb Ratio4.172.812.211.350.981.03
Book Value Per Share6.228.976.754.653.263.1
Free Cash Flow Yield(0.0717)(0.0596)(0.1)(0.25)(0.47)(0.45)
Capex To Depreciation10.18.692.050.360.110.1
Pb Ratio4.172.812.211.350.981.03
Inventory Turnover(0.0828)(0.0558)(0.65)(0.27)(0.31)(0.32)
Net Income Per Share(1.83)(1.94)(1.8)(2.3)(2.09)(2.19)
Days Of Inventory On Hand(4.4K)(6.5K)(559.33)(1.4K)(1.2K)(1.3K)
Payables Turnover0.541.111.271.241.1943.25
Cash Per Share9.3413.938.057.212.862.72
Pocfratio(19.12)(26.4)(10.96)(4.08)(2.12)(2.22)
Capex To Operating Cash Flow(0.37)(0.57)(0.12)(0.0235)(0.006377)(0.006696)
Pfcf Ratio(13.96)(16.78)(9.82)(3.99)(2.11)(2.21)
Days Payables Outstanding671.62328.6286.5303.088.868.42
Income Quality0.740.460.720.660.730.47
Roe(0.29)(0.22)(0.27)(0.5)(0.64)(0.67)
Ev To Operating Cash Flow(15.2)(17.9)(6.96)(1.9)(2.17)(2.28)
Pe Ratio(14.22)(13.01)(8.28)(2.73)(1.54)(1.62)
Return On Tangible Assets(0.26)(0.19)(0.24)(0.4)(0.51)(0.53)
Ev To Free Cash Flow(11.1)(11.38)(6.24)(1.86)(2.16)(2.26)
Earnings Yield(0.0703)(0.0768)(0.12)(0.37)(0.65)(0.62)
Net Debt To E B I T D A2.993.94.361.5(0.0398)(0.0379)
Current Ratio16.468.9616.89.712.3814.71
Tangible Book Value Per Share6.228.976.754.653.263.1
Graham Number15.9919.7816.5415.5312.3822.54
Shareholders Equity Per Share6.228.976.754.653.263.1
Capex Per Share0.50.550.160.03630.009660.009177
Graham Net Net8.1811.847.085.932.031.93
Enterprise Value Over E B I T D A(11.61)(8.21)(7.58)(1.3)(1.72)(1.63)
Price Earnings Ratio(14.22)(13.01)(8.28)(2.73)(1.54)(1.62)
Price Book Value Ratio4.172.812.211.350.981.03
Days Of Payables Outstanding671.62328.6286.5303.088.868.42
Price To Operating Cash Flows Ratio(19.12)(26.4)(10.96)(4.08)(2.12)(2.22)
Price To Free Cash Flows Ratio(13.96)(16.78)(9.82)(3.99)(2.11)(2.21)
Effective Tax Rate0.001790.06690.04730.0084690.0076220.007241

Pair Trading with Allogene Therapeutics

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Allogene Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Allogene Therapeutics will appreciate offsetting losses from the drop in the long position's value.

Moving together with Allogene Stock

  0.76VALN Valneva SE ADRPairCorr

Moving against Allogene Stock

  0.69DRTS Alpha Tau MedicalPairCorr
  0.64CDIOW Cardio DiagnosticsPairCorr
  0.61VCYT VeracytePairCorr
  0.6VCEL Vericel Corp OrdPairCorr
  0.58DMAC DiaMedica Therapeutics Upward RallyPairCorr
The ability to find closely correlated positions to Allogene Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Allogene Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Allogene Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Allogene Therapeutics to buy it.
The correlation of Allogene Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Allogene Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Allogene Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Allogene Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
When determining whether Allogene Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Allogene Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Allogene Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Allogene Therapeutics Stock:
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Allogene Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.
To learn how to invest in Allogene Stock, please use our How to Invest in Allogene Therapeutics guide.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Allogene Therapeutics. If investors know Allogene will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Allogene Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.55)
Quarterly Revenue Growth
(0.27)
Return On Assets
(0.26)
Return On Equity
(0.54)
The market value of Allogene Therapeutics is measured differently than its book value, which is the value of Allogene that is recorded on the company's balance sheet. Investors also form their own opinion of Allogene Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Allogene Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Allogene Therapeutics' market value can be influenced by many factors that don't directly affect Allogene Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Allogene Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Allogene Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Allogene Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.